Vancouver, Canada--Xebra Brands Ltd., a cannabis company, announced last month in a press release that it has successfully cultivated and harvested its first cannabis crop in the Netherlands.
Samples of the crop were collected by the Dutch government's Bureau of Medicinal Cannabis ("BMC"), last Friday, March 25th. The crop consisted of high THC ±22% cannabis flower, and flower with balanced THC ±6% and CBD± 8%.
"We have demonstrated our operational excellence, with the delivery of our first trial crop on budget and on time," commented Rodrigo Gallardo, President of Xebra, in the press release. "We are extremely optimistic and confident as we now enter into the next phase of the cannabis cultivation pilot trial," further commented Mr. Gallardo.
As 1 of only 5 companies to be selected by the Dutch government to participate in the medicinal cannabis cultivation pilot trial, Xebra is endeavoring to be awarded 1 of 2 licenses, providing government-guaranteed revenues for each company of a minimum of ~US$80 million (€70.5 million), to supply all pharma-grade cannabis to be sold through pharmacies in the Netherlands.
The selection process includes the submission of samples from three cannabis trial crops, evaluated for certain criteria, including consistency and technical parameters. The deadline for the first crop was March 29, 2022, which has now been satisfied. The deadline for submission of the second crop is September 19, 2022, and March 6, 2023, for the third and final crop. A detailed business plan must also be provided to Dutch authorities by November 14, 2022. The announcement of the provisional award decision by the Dutch government is scheduled for April 3, 2023, with the commencement of a Framework Agreement for commercial operations planned for May 1, 2023.
Cultivation in the Netherlands is conducted in Xebra's indoor facility. Xebra's specific genetic varieties are characterized by high production, compact flowers of excellent quality, and fine-tasting terpene profiles, with a growth cycle of 12-16 weeks.
Read the entire press release.